Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03755791 · ClinicalTrials.gov registry record · Phase 3
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
A Phase 3 study of Hepatocellular Carcinoma, sponsored by Exelixis.
- Active
- Registry status
- Phase 3
- Development phase
- 837
- Enrollment target
- 20
- Study locations
NCT03755791 is a Phase 3 study of Hepatocellular Carcinoma that is active but no longer recruiting, run by Exelixis. The registered enrollment target is 837 participants, above the 252-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (232% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT03755791, a Phase 3 study of Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by Exelixis.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 837 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy. A single-agent cabozantinib arm will be enrolled in which participants receive single agent cabozantinib in order to determine its contribution to the overall safety and efficacy of the combination with atezolizumab.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Cabozantinib
- DRUG Sorafenib
Study Locations (20)
California
- Exelixis Clinical Site #44 - La Jolla
- Exelixis Clinical Site #112 - Los Angeles
- Exelixis Clinical Site #200 - Orange
- Exelixis Clinical Site #2 - Rialto
- Exelixis Clinical Site #207 - San Diego
- Exelixis Clinical Site #109 - San Francisco
- Exelixis Clinical Site #54 - San Francisco
Missouri
- Exelixis Clinical Site #11 - Kansas City
- Exelixis Clinical Site #5 - Kansas City
- Exelixis Clinical Site #8 - St Louis
Arizona
- Exelixis Clinical Site #208 - Phoenix
- Exelixis Clinical Site #159 - Tucson
Illinois
- Exelixis Clinical Site #195 - Chicago
- Exelixis Clinical Site #120 - Chicago
District of Columbia
- Exelixis Clinical Site #58 - Washington D.C.
Florida
- Exelixis Clinical Site #191 - Miami
Georgia
- Exelixis Clinical Site #4 - Atlanta
Maryland
- Exelixis Clinical Site #6 - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 837 participants |
| Start Date | 2018-06-10 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03755791
The ClinicalTrials.gov registry entry for NCT03755791 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 837 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 252-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (232% higher). The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.
NCT03755791 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Missouri, Arizona.
Frequently Asked Questions
What is clinical trial NCT03755791 about?
NCT03755791 is a clinical study titled "Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy". This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy. A single-agent cabozantinib arm will be enrol...
What is the current status of trial NCT03755791?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 837 participants. The study started on 2018-06-10. Estimated completion is 2026-07-31.
What conditions does trial NCT03755791 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT03755791?
The interventions under investigation include: Atezolizumab (DRUG), Cabozantinib (DRUG), Sorafenib (DRUG).
Who is sponsoring clinical trial NCT03755791?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03755791 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
RECRUITING · Phase 3
-
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
RECRUITING · Phase 3
-
Evaluating Novel Therapies in ctDNA Positive GI Cancers
RECRUITING · Phase 3
-
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
ACTIVE NOT RECRUITING · Phase 3
-
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.